A Phase II Trial of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous Non-Small Cell Lung Cancer

This was an open-label, multicenter, single-arm, Phase II trial of bevacizumab combined with first- or second-line therapy in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with previously treated central nervous system (CNS) metastases. A total of 115 patients enrolled in the study.

本研究为一项开放标签、多中心、单臂II期临床试验，旨在评估贝伐珠单抗（bevacizumab）联合一线或二线治疗方案，用于伴有既往经治疗的中枢神经系统（CNS）转移瘤的转移性非鳞状非小细胞肺癌（NSCLC）患者。本研究共纳入115例受试者。